Ganesh Moorthy

Ganesh Moorthy

AstraZeneca, Sweden - Södertälje / Sweden
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4532914
-
person_outline Ganesh Moorthy's MOST POPULAR ARTICLES
1-) A phase Ib study of the dual PI3K/mTOR inhibitor dactolisib (BEZ235) combined with everolimus in patients with advanced solid malignanciesTM Wise-Draper, G Moorthy, MA Salkeni, NA Karim, HE Thomas, ...Targeted oncology 12 (3), 323-332, 2017782017
2-) Harnessing meta‐analysis to refine an oncology patient population for physiology‐based pharmacokinetic modeling of drugsE Schwenger, VP Reddy, G Moorthy, P Sharma, H Tomkinson, E Masson, ...Clinical Pharmacology & Therapeutics 103 (2), 271-280, 2018382018
3-) Phase ia/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumorsEA Lim, JC Bendell, GS Falchook, TM Bauer, CG Drake, JH Choe, ...Clinical Cancer Research 28 (22), 4871-4884, 2022372022
4-) Evaluation of the drug–drug interaction potential of acalabrutinib and its active metabolite, ACP‐5862, using a physiologically‐based pharmacokinetic modeling approachD Zhou, T Podoll, Y Xu, G Moorthy, K Vishwanathan, J Ware, JG Slatter, ...CPT: pharmacometrics & systems pharmacology 8 (7), 489-499, 2019432019
5-) Abstract CT007: PETRA: first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutationsTA Yap, SA Im, AM Schram, A Sharp, J Balmana, RD Baird, JS Brown, ...American Association for Cancer Research (AACR), 2022412022